THE COST EFFECTIVENESS OF OMALIZUMAB FOR THE TREATMENT OF SEVERE ALLERGIC ASHTMA IN KOREA
Author(s)
Lee J, Ko S
Novartis Korea, Seoul, Korea, Republic of (South)
OBJECTIVES: Severe Allergic Asthma is a major cause of morbidity and mortality around the world, associated with a heavy societal burden in Korea .The aim of this study was to evaluate the cost-effectiveness of Omalizumab compared with standard therapy in the treatment of severe allergic asthma patients over 12 years old from health-care perspective in Korea. METHODS: A Markov model was developed to evaluate the cost-effectiveness of Omalizumab added to standard therapy comparing with standard therapy. 1-month cycle model with 5 states (stable, clinically non-severe exacerbation, clinically sever exacerbation, death due to severe exacerbation, and all-cause death) was to project costs and QALYs over 30 years. Effectiveness and utility data were mainly derived from INNOVATE trial. Death rate due to exacerbation is based on Korean-specific data. Direct medical cost based on health states were obtained from 3 hospitals in Korea. Annual discount rate was 5%. One-way sensitivity analysis was performed to confirm the robustness of the model. Exchange rate used was 1,123 KRW per USD (2017 June). RESULTS: Total expected cost and QALYs of Omalizumab added to standard therapy versus standard therapy alone was USD 50,899, 8.04 QALYs gained respectively for 30 years. Incremental cost per QALYs gained was 23,589 dollar per QALY gained. The model appeared to be most sensitive to changes in the death rate due to exacerbation. One- way sensitivity analysis showed that ICER of add- on therapy group with Omalizumab compared with standard of therapy was from 17,839 to 29,870 dollar per QALY gained. CONCLUSIONS: Considering Omalizumab is an orphan drug, this option is likely to be cost-effective option for adults with severe allergic asthma compared with standard therapy alone in Korea.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRS44
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders